Markets
A smaller cut is narrowly expected, but a more aggressive move is possible.
Stocks
Obesity drug stocks: Why it will be ‘exceptionally difficult’ to dethrone Eli Lilly and Novo Nordisk
The two biggest players in the market appear poised to dominate for years to come.
Markets
Everything investors need to know about frothy stock valuations, and why they may not be so bad.